Compare Charles River Laboratories Intl. Inc (CRL) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Omnicom Group Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while Omnicom Group Inc. trades at $81.48 (market cap $23.01B). The key difference: Omnicom Group Inc. is far larger — about 2.1× Charles River Laboratories Intl. Inc's market cap, and Omnicom Group Inc. pays a 3.96% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | OMC | |
|---|---|---|
Market Cap | $11.14B | $23.01B |
Sector | Health | Media |
52-Week High | $233.60 | $85.80 |
52-Week Low | $145.57 | $67.27 |
Enterprise Value | $14.00B | $30.24B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Omnicom Group (OMC) trades at $82.55, up 0.76% today, with a bullish technical signal from moving averages. The stock shows mixed earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results due July 28, 2026. Revenue grew to $17.27B in 2025, though net income was negative, and cash flow improved significantly. Recent news highlights partnerships with IBM, Netflix, and NBCUniversal, enhancing its media and advertising solutions.
Outlook is cautiously optimistic with a consensus price target of $105.75, implying 28% upside, but risks include intense competition and thin profit margins. The stock offers value with a P/E of 12.16 and a dividend, yet investors should monitor earnings sustainability and debt levels amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
